Rachid Ayari Takes Charge As Interim MD Of Sanofi India, Replacing Rodolfo Hrosz
Sanofi India’s Board of Directors has appointed Rachid Ayari as Interim Managing Director (MD) for six months starting July 21, 2025, in addition to his role as Chief Financial Officer (CFO). His appointment will remain effective until January 20, 2026, or until a permanent MD is appointed.
Ayari has replaced Rodolfo Hrosz, who retired from the same position effective April 30, 2025.
Further, Aniket Raje has been appointed as the Head of Regulatory Affairs of the company, with effect from August 1, 2025.
Ayari has over 8 years of experience at Sanofi and previously spent 16 years at Pfizer. He brings extensive knowledge in key areas of finance and has held CFO roles across multiple geographies, including North Africa, Russia, Central Asia, and India. His expertise includes financial management, collaboration with cross-functional teams, and adherence to regulatory and corporate compliance standards. His diverse international background supports his leadership role in managing complex financial operations in the pharmaceutical sector.
Raje has over 21 years of experience in the technical departments of the pharmaceutical industry. His expertise spans product registration, life-cycle management, stakeholder engagement, and leadership roles. Before his current appointment, he was associated with Sanofi Healthcare India Private Limited, a Sanofi Group company, as Head of Regulatory Affairs for Vaccines and Rare Diseases. He holds a master’s degree (M.Sc) in clinical biochemistry from G.S. Medical College and K.E.M. Hospital, Mumbai University.
